Contribution of the NH2-terminal EGF-domain of factor IXa to the specificity of intrinsic tenase

Summary

Factor IXa (FIXa) is a vitamin K-dependent coagulation serine protease which binds to factor VIIIa (FVIIIa) on negatively charged phospholipid vesicles (PCPS) to catalyse the activation of factor X (FX) to factor Xa (FXa) in the intrinsic pathway. Fluorescence resonance energy transfer (FRET) studies have indicated that the Gla-domain-dependent interaction of FIXa and FX with PCPS in the presence of FVIIIa positions the active-site of the protease at an appropriate height above the membrane surface to optimise the catalytic reaction. In this study, we investigated the contribution of the NH2-terminal EGF-domain (EGF1) of FIXa to the recognition specificity of intrinsic tenase by constructing an EGF1 deletion mutant of FIXa (FIXa-desEGF1) and characterising the properties of the mutant in kinetic, direct binding and FRET assays. The results of direct binding and kinetic studies demonstrated that the binding affinity of the mutant for interaction with FVIIIa on PCPS has been impaired greater than 10-fold and the catalytic efficiency of the mutant protease FVIIIa-PCPS complex in the activation of FX has been decreased 100-fold. By contrast, the mutant protease exhibited a normal activity toward FX in the absence of the protein cofactor. FRET measurements revealed that the distance of the active-site of the mutant FIXa relative to PCPS vesicles has been decreased 10 Åfrom 75 ±2 Åfor FIXa to 65 ±2 Åfor FIXa-desEGF1 independent of FVIIIa. These results suggest that the NH2-terminal EGF-domain of FIXa provides a binding-site for FVIIIa and plays an essential spacer function in the intrinsic tenase complex.

Keywords

Factor IXa - factor VIIIa - intrinsic tenase - FRET - Gla-domain - EGF-domains

^* These authors contributed equally to this study.

• References

• 1 Jackson CM, Nemerson Y. Blood coagulation. Ann Rev Biochem 1980; 49: 765-811.
• 2 Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505-518.
• 3 Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintenance and regulation. Biochemistry 1991; 30: 10363-10370.
• 4 Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82: 165-174.
• 5 Thompson AR. Structure, function, and molecular defects of factor IX. Blood 1986; 67: 565-572.
• 6 Hopfner K-P, Brandstetter H, Karcher A. et al. Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants. EMBO J 1997; 16: 6626-6635.
• 7 Mertens K, Celie PHN, Kolkman JA. et al. Factor VIII-factor IX interactions: molecular sites involved in zymogen-cofactor complex assembly. Thromb Haemost 1999; 82: 209-217.
• 8 Chang J, Jin J, Lollar P. et al. Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J Biol Chem 1998; 273: 12089-12094.
• 9 Stenflo J. Structure-function relationships of epidermal growth factor modules in vitamin K-dependent clotting factors. Blood 1991; 78: 1637-1651.
• 10 Mathur A, Bajaj SP. Protease and EGF1 domains of factor IXa play distinct role in binding to factor VIIIa. Importance of helix 330 (helix 162 in chymotrypsin of protease domain of factor IXa in its interaction with factor VIIIa. J Biol Chem 1999; 274: 18477-18486.
• 11 Schmidt AE, Bajaj SP. Structure-function relationships in factor IX and factor IXa. Trends Cardiovasc Med 2003; 13: 39-45.
• 12 Blostein MD, Furie BC, Rajotte I. et al. The Gla domain of factor IXa binds to factor VIIIa in the tenase complex. J Biol Chem 2003; 278: 31297-31302.
• 13 Chang JY, Monroe DM, Stafford DW. et al. Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B. J Clin Invest 1997; 100: 886-892.
• 14 Lin SW, Smith KJ, Welsch D. et al. Expression and characterization of human factor IX and factor IX-factor X chimeras in mouse C127 cells. J Biol Chem 1990; 265: 144-150.
• 15 Bode W, Mayr I, Baumann U. et al. The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 1989; 8: 3467-3475.
• 16 Yang L, Gopalakrishna K, Manithody C. et al. Expression, purification and characterization of factor IX derivatives using a novel vector system. Protein Expr Purif 2006; 50: 196-202.
• 17 Yang L, Manithody C, Olson ST. et al. Contribution of basic residues of the autolysis loop to the substrate and inhibitor specificity of factor IXa. J Biol Chem 2003; 278: 25032-25038.
• 18 Rezaie AR, Fiore MM, Neuenschwander PF. et al. Expression and purification of a soluble tissue factor fusion protein with an epitope for an unusual calcium-dependent antibody. Prot Exp Purif 1992; 3: 453-460.
• 19 Neuenschwander PF, Bianco-Fisher E, Rezaie AR. et al. Phosphatidylethanolamine augments factor VIIa-tissue factor activity: Enhancement of sensitivity to phosphatidylserine. Biochemistry 1995; 34: 13988-13993.
• 20 Qureshi SH, Yang L, Yegneswaran S. et al. FRET studies with factor X mutants provide insight into the topography of the membrane-bound factor X/Xa. Biochem J 2007; 407: 427-433.
• 21 Mutucumarana V P, Duffy EJ, Lollar P. et al. The active site of factor IXa is located far above the membrane surface and its conformation is altered upon association with factor VIIIa: A fluorescence study. J Biol Chem 1992; 267: 17012-17021.
• 22 Yegneswaran S, Smirnov MD, Safa O. et al. Relocating the active site of activated protein C eliminates the need for its protein S cofactor. J Biol Chem 1999; 274: 5462-5468.
• 23 Huang C, Mason JT. Geometric packing constraints in egg phosphatidylcholine vesicles. Proc Natl Acad Sci USA 1978; 75: 308-310.
• 24 Bock PE. Active site selective labeling of serine proteases with spectroscopic probes using thioester peptide chloromethyl ketones: Demonstration of thrombin labeling using Nα-[(acetylthio)acetyl]-D-Phe-Pro-Arg-CH2Cl. Biochemistry 1988; 27: 6633-6639.
• 25 Duffy EJ, Parker ET, Mutucumarana VP. et al. Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles. J Biol Chem 1992; 267: 17006-17011.
• 26 Qureshi SH, Yang L, Manithody C. et al. Membrane-dependent interaction of factor Xa and prothrombin with factor Va in the prothrombinase complex. Biochemistry 2009; 48: 5034-5041.
• 27 Betz A, Krishnaswamy S. Regions remote from the site of cleavage determine macromolecular substrate recognition by the prothrombinase complex. J Biol Chem 1998; 273: 10709-10718.
• 28 Husten EJ, Esmon CT, Johnson AE. The active site of blood coagulation factor Xa: its distance from the phospholipid surface and its conformational sensitivity to components of the prothrombinase complex. J Biol Chem 1987; 262: 12953-12962.
• 29 McCallum CD, Hapak RC, Neuenschwander PF. et al. The location of the active site of blood coagulation factor VIIa above the membrane surface and its reorientation upon association with tissue factor. A fluorescence energy transfer study. J Biol Chem 1996; 271: 28168-28175.
• 30 Manithody C, Yang L, Rezaie AR. Identification of a basic region on tissue factor that interacts with the first epidermal growth factor-like domain of factor X. Biochemistry 2007; 46: 3193-3199.